Dana-farber Cancer Institute

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the dru…

This study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…

This study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …

This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…

This study tests a program to help women with ER-positive breast cancer in Rwanda take their daily hormone therapy as prescribed. The program includes education, reminders, and behavioral support. Researchers will measure how well participants stick with their medication and how …

This phase 2 trial tests a drug called FHD-286 in 20 people with a specific type of small-cell lung cancer that has a marker called POU2F3. Participants take the drug by mouth once daily in 21-day cycles. The main goal is to see if the drug can shrink tumors.

This study is for adolescents and young adults (ages not specified) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Researchers want to see if a specific combination of chemotherapy drugs plus the immunotherapy blinatumomab helps more pat…

This study will test the GRAIL Galleri blood test, which looks for signs of many different cancers in a single blood draw. Researchers will enroll 100 adults who have symptoms that might be cancer. The goal is to see how well the test detects cancer and how it compares to standar…

This study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…

This trial tests whether sending AI-generated summaries of a patient's serious illness conversations to their care team at hospital admission can improve care. The summaries, created by a large language model, highlight the patient's goals and preferences. The study enrolls adult…

This trial tests whether a smartphone app called LISTEN can help people with brain tumors who have trouble speaking (aphasia) communicate more easily. The app uses artificial intelligence to adapt to each user's needs and can be used with voice input and output. Researchers will …

This trial tests whether a wearable device that delivers a cooling sensation on the wrist can reduce the burden of hot flashes in men with prostate cancer who are on androgen deprivation therapy (ADT). About 66 participants will be randomly assigned to use the device right away o…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study tests whether a personalized exercise program can improve physical function and quality of life in adolescents and young adults who have survived sarcoma. Participants first complete a triage tool to assess their needs, then receive a 12-week exercise plan that may inc…

This study tests whether adding acupuncture to virtual exercise can help manage nerve pain caused by a specific bladder cancer treatment (EV-Pembro). About 50 adults with advanced bladder cancer will be split into two groups: one gets acupuncture plus virtual exercise, the other …

This study tests an educational program called SHARE-MC designed to help women with metastatic breast cancer address sexual health issues. About 96 women will take part in group video sessions or receive an informational booklet. The goal is to see if the program improves sexual …

This study explores whether self-administered digital cognitive tests can accurately measure thinking skills like attention, memory, and processing speed in people with primary central nervous system lymphoma or low-grade gliomas. Participants will complete both digital tests (on…

This study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stig…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …

This study aims to create a nutrition algorithm called NACHO that suggests foods and recipes tailored to cancer patients' needs. Researchers will work with dietitians, clinicians, and patient advisors to develop the tool, then test it with 130 patients who are undergoing or have …